GLP's
Tirzepatide
15 mg
Dual incretin agonist (GIP / GLP-1)
$55
Research overview
Tirzepatide is a dual GIP and GLP-1 receptor agonist. FDA-approved products containing tirzepatide have specific clinical indications, while research-grade material should be discussed only in lawful research context and never as an informal treatment substitute.
Potential research areas
- Incretin signaling
- Glucose regulation pathways
- Metabolic syndrome research
- Appetite and satiety models
- Form
- Lyophilized Powder
- Category
- Research Peptide
- Use
- Research Only
Current evidence varies by compound. Many products discussed in this guide remain investigational, are not approved for general clinical use, and should only be handled under qualified research protocols.
No dosing, administration, or treatment instructions are provided.